Why Eli Lilly Stock Jumped This Week
Key Points
Mounjaro and Zepbound are driving Eli Lilly's earnings sharply higher.
Foundayo looks like another top-seller.
- 10 stocks we like better than Eli Lilly ›
Shares of Eli Lilly (NYSE: LLY) rose this past week after the medicine maker reported skyrocketing profits fueled by sales of its blockbuster weight loss drugs.
Image source: Getty Images.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Demand for GLP-1 drugs is booming
Eli Lilly's revenue surged 56% year over year to $19.8 billion in the first quarter.
The healthcare giant has been working with regulators to lower prices for several of its products. But these discounts were more than offset by volume gains. In all, realized prices declined by 13%, while volume climbed 65%.
The company's massively popular GLP-1 drugs Mounjaro and Zepbound were particularly powerful growth drivers, with sales rising 125% and 80%, respectively, to $8.7 billion and $4.2 billion.
All told, Eli Lilly's adjusted net income soared 155% to $7.7 billion, or $8.55 per share. That handily exceeded Wall Street's estimates, which had called for per-share profits of $6.79.
Foundayo should help to expand the GLP-1 market
These excellent results prompted Eli Lilly to raise its revenue and adjusted earnings per share targets to $82 billion to $85 billion and $35.50 to $37. That's up from a prior forecast of $80 billion to $83 billion and $33.50 to $35.
The drugmaker's new GLP-1 pill, Foundayo, is expected to fuel further gains. The once-daily pill is a more convenient option than Eli Lilly's injectable GLP-1 drugs. More than 20,000 people are already taking the recently FDA-approved pill just several weeks after its launch.
"Foundayo will meaningfully expand the number of people who can benefit from GLP-1s," CEO David Ricks said.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $496,473!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,216,605!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 3, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
